• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    526.13 -9.44 (-1.76%)
    Streaming Delayed Price Updated: 11:38 AM EDT, Jul 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about United Therapeutics Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    News headline image
    United Therapeutics Corporation Acquires Thymmune Therapeutics
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
    Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next ... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
    As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
    Via StockStory
    Topics Artificial Intelligence
    United Therapeutics (NASDAQ:UTHR) Shares Dip After Q1 2026 Earnings Miss ↗
    Via Chartmill
    News headline image
    These 3 Stocks Lowered Their Share Counts Drastically in Q1 ↗
    Pinterest, Southwest Airlines, and United Therapeutics each executed significant share repurchases in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2%, respectively. 
    Via MarketBeat
    News headline image
    1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
    Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
    Via StockStory
    Topics Energy
    News headline image
    What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
    Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down
    Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
    Via StockStory
    Topics Credit Cards
    News headline image
    United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
    United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attribu... 
    Via StockStory
    Topics Earnings
    News headline image
    United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook
    Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to... 
    Via StockStory
    News headline image
    UTHR Q1 2026 Earnings Transcript ↗
    UTHR Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
    Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to $781.... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Reports First Quarter 2026 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
    From MannKind
    Via GlobeNewswire
    News headline image
    United Therapeutics (UTHR) Q1 Earnings Report Preview: What To Look For
    Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before market hours. Here’s what to look for. United Therape... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    The eVTOL Era is Beginning With Uber and Joby Aviation: What Investors Need to Know ↗
    The eVTOL market is preparing for takeoff in 2026, but which stocks will win out over the long term? 
    Via The Motley Fool
    News headline image
    United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    UTHR Q4 2025 Earnings Transcript ↗
    UTHR Q4 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Reasons Investors Love United Therapeutics (UTHR)
    Since April 2021, the S&P 500 has delivered a total return of 68.6%. But one standout stock has more than doubled the market - over the past five years, Unit... 
    Via StockStory
    Topics Stocks
    News headline image
    United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Market-Beating Stocks for Long-Term Investors
    Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
    Via StockStory
    Topics Energy
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.